Limits...
Modelling vaccination schedules for a cancer immunoprevention vaccine.

Motta S, Castiglione F, Lollini P, Pappalardo F - Immunome Res (2005)

Bottom Line: This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma.In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma.We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Mathematics and Computer Science, University of Catania, Catania, Italy. motta@dmi.unict.it

ABSTRACT
We present a systematic approach to search for an effective vaccination schedule using mathematical computerized models. Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine. This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic vaccination was less efficient. In the present paper we use the computer simulations to systematically search for a vaccination schedule which prevents solid tumor formation. The strategy we used for defining a successful vaccination schedule is to control the number of cancer cells with vaccination cycles. We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

No MeSH data available.


Related in: MedlinePlus

Tumor-free survival curves of HER-2/neu transgenic mice receiving the Triplex vaccine according to different protocols from [6]. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC1287065&req=5

Figure 1: Tumor-free survival curves of HER-2/neu transgenic mice receiving the Triplex vaccine according to different protocols from [6]. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.

Mentions: A complete prevention of mammary carcinogenesis with the Triplex vaccine was obtained when vaccination cycles started at 6 weeks of age and continued for the entire duration of the experiment, at least one year (chronic vaccination). One vaccination cycle consisted of four intraperitoneal administrations of non-replicating (mitomycin-treated) VC over two weeks followed by two weeks of rest [8]. We made various attempts at reducing the number of vaccination cycles, in particular we studied the effects of just three cycles starting at 6 weeks of age (early vaccination), or at 10 weeks of age (late vaccination), or at 16 weeks of age (very late vaccination). Early vaccination produced a significant delay in the onset of tumors, but all mice eventually succumbed to mammary carcinoma. Late vaccination was less effective than early vaccination, whereas the very late protocol was completely devoid of effect in comparison to untreated control mice (Figure 1).


Modelling vaccination schedules for a cancer immunoprevention vaccine.

Motta S, Castiglione F, Lollini P, Pappalardo F - Immunome Res (2005)

Tumor-free survival curves of HER-2/neu transgenic mice receiving the Triplex vaccine according to different protocols from [6]. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC1287065&req=5

Figure 1: Tumor-free survival curves of HER-2/neu transgenic mice receiving the Triplex vaccine according to different protocols from [6]. Each arrow at the bottom of the graph represents one cycle of vaccination. The sequence of neoplastic progression in untreated mice is outlined under the x axis; CIS, carcinoma in situ.
Mentions: A complete prevention of mammary carcinogenesis with the Triplex vaccine was obtained when vaccination cycles started at 6 weeks of age and continued for the entire duration of the experiment, at least one year (chronic vaccination). One vaccination cycle consisted of four intraperitoneal administrations of non-replicating (mitomycin-treated) VC over two weeks followed by two weeks of rest [8]. We made various attempts at reducing the number of vaccination cycles, in particular we studied the effects of just three cycles starting at 6 weeks of age (early vaccination), or at 10 weeks of age (late vaccination), or at 16 weeks of age (very late vaccination). Early vaccination produced a significant delay in the onset of tumors, but all mice eventually succumbed to mammary carcinoma. Late vaccination was less effective than early vaccination, whereas the very late protocol was completely devoid of effect in comparison to untreated control mice (Figure 1).

Bottom Line: This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma.In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma.We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Mathematics and Computer Science, University of Catania, Catania, Italy. motta@dmi.unict.it

ABSTRACT
We present a systematic approach to search for an effective vaccination schedule using mathematical computerized models. Our study is based on our previous model that simulates the cancer vs immune system competition activated by tumor vaccine. This model accurately reproduces in-vivo experiments results on HER-2/neu mice treated with the immuno-prevention cancer vaccine (Triplex) for mammary carcinoma. In vivo experiments have shown the effectiveness of Triplex vaccine in protection of mice from mammary carcinoma. The full protection was conferred using chronic (prophylactic) vaccination protocol while therapeutic vaccination was less efficient. In the present paper we use the computer simulations to systematically search for a vaccination schedule which prevents solid tumor formation. The strategy we used for defining a successful vaccination schedule is to control the number of cancer cells with vaccination cycles. We found that, applying the vaccination scheme used in in-vivo experiments, the number of vaccine injections can be reduced roughly by 30%.

No MeSH data available.


Related in: MedlinePlus